美丽田园2025年盈利预告：预计净利润同比增长不少于34%

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has released a positive profit forecast for the fiscal year 2025, expecting revenue of at least 3 billion yuan, a growth of no less than 16% compared to 2024, and an adjusted net profit of at least 380 million yuan, representing a year-on-year increase of no less than 40% [1][3]. Group 1: Revenue and Profit Forecast - The company anticipates a revenue of no less than 3 billion yuan for 2025, which is an increase of at least 16% from the previous year [1]. - Adjusted net profit is expected to be no less than 380 million yuan, reflecting a year-on-year growth of at least 40% [1]. - The net profit is projected to be no less than 340 million yuan, indicating a year-on-year increase of at least 34% [1]. Group 2: Factors Influencing Performance - The company attributes its performance to two main factors: external acquisitions and organic business growth [3][4]. - The acquisition of the second-largest brand in the Chinese beauty industry, Nairui'er, has expanded the company's business coverage and improved its adjusted net profit margin from 6.5% to 10.4% in the first half of 2025 [3]. - The company has also completed the acquisition of the third-largest beauty service brand, Siyuanli, further consolidating its position in the industry [3]. Group 3: Business Strategy and Future Outlook - The company is focusing on high-end female consumer groups in major cities, responding to the growing "self-indulgent consumption" demand, which has boosted same-store revenue [4]. - In November 2025, the company announced three strategic directions: "Super Brand," "Super Chain," and "Super Digitalization," aimed at exploring the high-end beauty service sector [5]. - The company plans to continue its dual-driven strategy of "organic growth + external acquisitions" and deepen its "dual beauty + dual healthcare" business model [5].